Dr. Manar AL-Moneef is the General Director of Health Care & Life sciences at the Saudi Arabian General Investment Authority (SAGIA), which is the government agency responsible for promoting investments in the Kingdom and improving its investment environment. At SAGIA, Dr. Al-Moneef is responsible for the creation of new health care initiatives, updating current laws and regulations and promoting investments in life sciences & Health care.

Prior to joining SAGIA, Dr. Al-Moneef was the Director of Molecular Pathology & Genetics in King Abdulaziz medical city, National Guard Hospital, Riyadh, Saudi Arabia. During that time she evaluated different research projects which involved the development of a novel assay. She was also appointed as an assistant professor in king Saud University for Medical Studies.

Dr. AL-Moneef has many publications in molecular medicine. Dr. AL-Moneef has a PhD in molecular genetics of cancer from Leicester Warwick University, United Kingdom and a Master in molecular medicine form Cambridge University, United Kingdom.

(CBS) Thalia Assuras has been a national correspondent, based in Washington, D.C., for CBS News' The Early Show since January 2002.

She also serves as one of the primary anchors of the Saturday edition of the CBS Evening News and as a CBS Newscorrespondent, contributing to many broadcasts.

Previously, Assuras co-anchored The Saturday Early Show (1999-2001). She also served as co-anchor of CBS News' weekday morning news broadcast, This Morning (1999) and anchored the early morning CBS Morning News.

Assuras has been a CBS News correspondent since 1997, reporting for a variety of CBS News broadcasts. She has filed numerous international stories, including reports from Iraq, where she covered the U.S. military action following the fall of Saddam Hussein and was one of the first television journalists to report live from Tikrit only hours after his capture. She also covered the aftermath of the deadly earthquake in Bam, Iran and the Kosovo refugee crisis in Albania. Assuras has also covered a wide range of domestic stories, including the 9/11 attacks in New York, the Elian Gonzalez controversy and Hurricane Floyd, and has interviewed world leaders ranging from President Bill Clinton to the late Israeli Prime Minister Yitzhak Rabin.

She also has substitute-anchored the CBS Morning News and This Morning. Before that, Assuras served as co-anchor of the live daily program about people in the day's news, which ran on the CBS cable channel, "Eye on People" (1997).

Assuras joined CBS News from ABC, where she was an anchor for "World News Now" and "World News This Morning" (1993-96) and a general assignment correspondent.

Previously, she anchored "Canada AM," CTV's morning news broadcast, co-anchored "Canada AM Weekend" and substitute-anchored the "CTV Weekend News" (1992-93). Assuras also served as a field correspondent.

She is the recipient of several journalism awards including the Marie Torre Memorial Award (2001), a Sigma Delta Chi Award for Journalism, a Canadian MediaWatch Award and a University of Western Ontario Journalism Award.

Assuras was born in London, Ontario, Canada. She was graduated from the University of Western Ontario with an honors bachelor of science degree/ microbiology and immunology and with a master's degree in journalism. Assuras lives in the Washington D.C. area.

Anthony Atala, MD, is the W.H. Boyce Professor and Chair of the Department of Urology and Director of the Institute for Regenerative Medicine at Wake Forest University. Dr. Atala is a surgeon in the area of pediatric urology and a researcher in the area of regenerative medicine. His current work focuses on growing new human cells, tissues and organs.

Dr. Atala works with several journals and serves in various roles, such as Editor-in-Chief of Current Stem Cell Research and Therapy and the Scientific World-Urology; as Associate or Section Editor of the Journal of Urology (Investigative Urology), Tissue Engineering and Regenerative Medicine, The Journal of Rejuvenation Research, and Current Reviews in Urology; and as Editorial Board member of the Journal of the American College of Surgeons, Urology, Current Opinion in Urology, BioMed Central-Urology, the Journal of Laparoendoscopic and Advanced Surgical Techniques, Stem Cells and Development, Expert Opinion on Biological Therapy, and Biomedical Materials.

Dr. Atala is a recipient of the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, and the Gold Cystoscope Award for advances in his field. Dr. Atala was named by Scientific American as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration. In 2006, he was named by Fast Company magazine as one of 50 people who “will change how we work and live over the next 10 years, and his work was listed as Discover Magazine`s Number 1 Top Science Story of the Year in the field of medicine in 2007. A Time Magazine poll ranked Dr. Atala as the 56th most influential person of the year in 2007.

Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, and the National Institutes of Health Bioengineering Consortium. He is currently an NIH “Quantum Grant” awardee. Dr. Atala heads a team of over 150 physicians and researchers. Ten applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is the editor of 8 books, including Methods of Tissue Engineering, Principles of Regenerative Medicine, and Minimally Invasive Urology, and has published more than 200 journal articles and has applied for or received over 200 national and international patents.

Matthew D. Barber, MD, MHS, is a Staff Physician in the Section of Urogynecology and Pelvic Reconstructive Surgery and Director of Clinical Research in the Department of Obstetrics and Gynecology at Cleveland Clinic's main campus. He is also on Staff at the Glickman Urological Institute at Cleveland Clinic and is an Associate Professor of Surgery at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

Prior to joining the Cleveland Clinic in 2001, he was an associate in the Department of Obstetrics and Gynecology at Duke University Medical Center in Durham, North Carolina. He is a fellow of the American College of Obstetrics and Gynecology and a diplomate of the American Board of Obstetrics and Gynecology.

Dr. Barber's specialty interests include pelvic organ prolapse, urinary incontinence, fecal incontinence, vesicovaginal and rectovaginal fistulas, as well as chronic vulvar and vaginal conditions.

Dr. Barber received his medical degree from Thomas Jefferson Medical College in Philadelphia, Pennsylvania, where he graduated summa cum laude. He then went on to Duke University, where he earned a Master of Health Sciences degree in Clinical Research and completed a residency in obstetrics and gynecology, as well as a fellowship in urogynecology and pelvic reconstructive surgery. He is licensed to practice medicine in Ohio and North Carolina.

He is lead or co-author on several research studies published in peer-reviewed publications or presented at leading medical conferences in his field. He is also author or co-author of chapters from several medical textbooks, and he regularly gives presentations and seminars. Dr. Barber has won numerous academic awards and research grants, including, to name only a few, the National Faculty Award from the American College of Obstetrics and Gynecology & The Council on Resident Education in Obstetrics and Gynecology (2005), Teacher of the Year in Obstetrics and Gynecology at Cleveland Clinic (2002-03 and 2004-05) and the Society for Gynecologic Surgeons Prize Paper (2006).

Maria Bartiromo is the anchor of CNBC's "Closing Bell with Maria Bartiromo," and host and managing editor of the nationally syndicated business, financial and economic news program, "Wall Street Journal Report with Maria Bartiromo," which was recently rated the most watched financial news program in America. It appears on over 200 stations weekly and provides the clarity, depth and insight of The Wall Street Journal in a television magazine format. She contributes to NBC's Today Show, Today In L.A., Today in Chicago and CNBC Asia's daily broadcasts.

Ms. Bartiromo joined CNBC in 1993 after five years as a producer and assignment editor with CNN Business News. In 1995, Ms. Bartiromo became the first journalist to report live from the New York Stock Exchange on a daily basis for Squawk Box. She reported from the NYSE for 10 years.

In May 2008, Ms. Bartiromo received a Gracie Award in the category of Outstanding Documentary for her documentary "Greenspan: Power, Money & the American Dream."

Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza.Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza.

In addition to being a member of the Board of Trustees of New York University, Bartiromo is on the Board of Directors of the New York City Ballet, the Girl Scout Council of Greater New York; as well as PENCIL, Public Education Needs Civic Involvement and Leadership, which is a non profit group focusing on improving New York high schools. She also is a Young Global Leader of the World Economic Forum, a member of The Wharton Leadership Advisory Board and a member of the Columbus Citizens Foundation.

Ms. Bartiromo graduated from New York University, where she majored in journalism and minored in economics.

Glen Bolger is one of the Republican Party's leading political strategists and pollsters. He is a partner and co-founder of Public Opinion Strategies, a national political and public affairs survey research firm whose clients include leading political figures, Fortune 500 companies, and major associations. Public Opinion Strategies has 20 U.S. Senators, eight governors, and more than 50 Members of Congress as clients.

Roll Call newspaper, a newspaper that covers Capitol Hill, noted Glen “has quickly emerged as the pollster of choice for House and Senate Republicans.”

In the 2006 elections, Glen handled the polling for two winning Senate campaigns, including Bob Corker of Tennessee, three winning Governor’s races, and five new Republican Members of Congress. Overall, Glen polls for twelve U.S. Senators, five Governors, and more than thirty Members of Congress.

In 2004, Glen handled the polling for six winning Senators, including John Thune of South Dakota, Richard Burr of North Carolina, Jim DeMint of South Carolina, Arlen Specter of Pennsylvania, and Jim Bunning of Kentucky. Glen also polled for 27 members of Congress, including four freshmen.

For its work in the 2002 elections, Public Opinion Strategies won the “Pollster of the Year” Campaign Excellence Award from the American Association of Political Consultants.

Roll Call has noted for three election cycles that Glen was one of the “Money 20”—consultants in both parties who make a difference.

In state legislative races, Glen has polled for successful Republican legislative candidates in Alabama, Georgia, Nevada, New Mexico, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, South Dakota, Virginia, and Washington State.

Glen's corporate polling experience includes crisis management polling for some of the top issues in recent years, as well as image and message work for major clients such as Wal-Mart, Blue Cross and Blue Shield of Florida, Tyson Foods, BNSF Railway, Intuit (the makers of Quicken), and numerous other Fortune 500 companies.

Prior to co-founding Public Opinion Strategies, Glen was the Director of Survey Research & Analysis for the National Republican Congressional Committee, the political arm of the House Republican Caucus. Glen is a graduate from The American University in Washington, D.C. Glen and his wife Carol have three daughters.

Is a bioengineering graduate from the University of San Diego with over twenty years of experience across a range of surgical specialties including General Surgery, Cardiac Surgery, gynecology, Urology and Orthopaedics, He has worked in the corporate sector ( American Hospital Supplies, Endolase, Laser Surgery Software Inc, RSP laboratories) pioneering techniques in endometrial ablation for menorrhagia, hysteroscopic female sterilization, laser tissue welding, laser software development, and ultrasonic decalcification of cardiac valve replacement, among other projects. He was the manager of BioEngineering Research Centre, a joint post- graduate research and development centre at Trinity College Dublin, and Staff Researcher at the Salk Institute in San Diego, California. By Preference he has mostly worked in the SME sector.

Advanced Surgical Concepts (ASC) was established in July 1998 to increase the number of Abdominal Surgeries performed endoscopically through the development of new access technologies.

Mr. Bonadio's company Advanced Surgical Concepts has developed a series of revolutionary access systems that will enable not just a select few, technically gifted pioneers who have overcome the difficulties presented by existing access devices and instruments, but all surgeons to utilize endoscopic approaches for abdominal surgery.

ASC has completed the first phase of a development strategy that will see us emerge in this major, evolving market as the world leader, in terms of both superior product and comprehensive intellectual property (IP) portfolio. We will forge partnerships with the leading multinational distribution companies in this market.

With over 50 patents filed, ASC has laid the IP groundwork for its phase II and III development strategies.

Steven Campbell, MD, PhD, is Professor of Surgery, Residency Program Director, and a member of the Section of Urologic Oncology in the Glickman Urological and Kidney Institute at Cleveland Clinic.

He obtained his medical degrees at the University of Chicago and completed his urology residency at Cleveland Clinic (1989-1995), followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center (1995-1996).

Dr. Campbell's primary interests include renal cell carcinoma, bladder cancer, prostate cancer, treatment-related osteoporosis and tumor angiogenesis. His background also includes American Foundation for Urologic Disease (AFUD) and Kimmel Research Scholarship awards, and he is a former member of the American Board of Urology Examination Committee. Dr. Campbell is currently on the educational board for AFUD and the medical advisory board for the Kidney Cancer Association.

Mike Connolly is CEO of Mirabilis Medica, an early-stage company based near Seattle. Mirabilis is developing a non-invasive treatment for uterine fibroids employing focused therapeutic ultrasound under guidance via imaging ultrasound. This leading-edge technology is designed to allow physicians to treat tissue deep inside the body without incisions, punctures or other damage to intervening tissue. Mike's prior experience includes having led a regional venture capital office for vSpring Capital, and cofounding several biomedical companies including women’s healthcare company Novacept (acquired by Cytyc/Hologic) and biomaterials company Cohesion (now part of AngioTech). Early in his career, Mike served as a Navy officer and a physics instructor at the U.S. Naval Academy. He holds a Stanford MBA, MIT M.S., U.S. Naval Academy B.S., and Professional Engineer license.

Charlie Cook is Publisher of The Cook Political Report, and political analyst for the National Journal Group, where he writes weekly for National Journal magazine and CongressDailyAM. He also writes a regular column for the Washington Quarterly, published by the Center for Strategic and International Studies, and is a political analyst for NBC News.

Widely regarded as one of the nation’s leading authorities on U.S. elections and political trends, Charlie has appeared on the ABC, CBS and NBC evening news programs, as well as on "Good Morning America," the "Today Show," "Nightline," "Meet the Press with Tim Russert," and "This Week…." He has also appeared many times on CNBC, MSNBC, CNN, C-SPAN, CNN and National Public Radio.

Before joining the National Journal Group in June of 1998, Charlie wrote for 12 years a twice-weekly column in Roll Call, the newspaper of Capitol Hill. Charlie also served as an election night analyst for CBS in 1990 and 1992, and for NBC in 1994, 1996, 1998, 2000, 2002 and 2004.

The New York Times has called Cook, "...one of the best political handicappers in the nation" and noted that The Cook Political Report is "...a newsletter that both parties regard as authoritative," while Bob Schieffer of CBS News has called the Cook Political Report, "the bible of the political community." The Wall Street Journal's Al Hunt once referred to Cook as "the Picasso of election analysis," while David Broder of The Washington Post has written that Charlie Cook is "perhaps the best non-partisan tracker of Congressional races."

Mihir Desai, MD, is Director of the Stevan B. Streem Center for Endourology at the Glickman Urological and Kidney Institute of Cleveland Clinic, and Associate Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr Desai’s clinical and research interests include stone disease, upper-urinary-tract obstruction, and laparoscopic and robotic surgery of the kidney, adrenal, prostate and bladder.

Dr. Desai has over 110 publications in peer-reviewed literature on minimally invasive therapies of the urinary tract. In addition, he has written over 15 book chapters and has presented abstracts and videos in many national and international meetings.

He has done pioneering work in the field of treatment of ureteropelvic obstruction, “scarless” laparoscopic surgery and flexible robotic applications for endoscopy. Many of these research works have won honors and awards at scientific meetings.

Dr. Desai is also Director of the Endourology Fellowship of the Endourological Society. He is an invited reviewer of many reputed journals and serves on several scientific committees

John Dineen is the President and CEO of GE Healthcare, a $17 billion segment of General Electric Company and the first GE business headquartered outside of the United States. GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. With expertise in diagnostic imaging, healthcare IT and the life-sciences, GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. John was appointed to his current role in July 2008.

From 2005, John was President and CEO of GE Transportation, a $4.5 billion global leader in the rail, mining, marine, drilling and wind industries.

John joined GE in 1986 as a telecommunications engineer in Rockville, Maryland. He has held a variety of leadership positions at GE, both in the U.S. and worldwide, including general manager of the Power Equipment business in Plainville, Connecticut; general manager of the Meter business in Somersworth, New Hampshire; general manager of the Microwave and Air-conditioning businesses in Louisville, Kentucky; manager of finance for GE Asia in Hong Kong; and president of GE Plastics Pacific. He has served in various assignments in Corporate Finance, and was vice president and general manager of Plastics at GE Advanced Materials.

John is a graduate of the University of Vermont where he earned bachelor's degrees in biology/genetics and computer science.

John and his wife Gina have two children.

Jonathan Emery, MD, has been providing general obstetrical and gynecologic care to patients in Northern Ohio since joining Cleveland Clinic in 2004. A board-certified Physician, he practices at the Cleveland Clinic Willoughby Hills Family Health Center and provides healthcare throughout the spectrum of women's lives, from adolescence through pregnancies and into middle age and menopause.

Dr. Emery has a special interest in treating abnormal uterine bleeding with alternatives to hysterectomy, including medical, radiologic and minimally invasive surgical techniques. A member of several professional societies, Dr. Emery has presented at clinical conferences and meetings for updates and advances in treating menstrual disorders including uterine fibroids and other abnormal bleeding conditions.

As an Assistant Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Dr. Emery regularly provides instruction to medical students and resident physicians and has won honors for his teaching in the past. He believes teaching patients is also important so that each woman can have an understanding of her condition.

Mr. Emmitt has over thirty years of health care industry investment experience including venture capital, investment research, and investment banking. As an investment analyst with Cyrus J. Lawrence and F. Eberstadt, Mr. Emmitt was recognized as one of the leading experts on the health care industry by Institutional Investor Magazine. He currently serves on the Boards of Directors of American Medical Systems, Inc., BioSet, ENTrigue Surgical, ev3 Inc, Galil Medical, Incumed, Tepha and Tornier. He previously served on the Boards of Directors of OsteoBiologics Inc., SciMed Life Systems, Xomed Surgical Products and Wright Medical. Mr. Emmitt received a B.A. in Economics from Bucknell University and an M.B.A. from The Rutgers School of Business.

Mr. Emerson, age 45, is the President and Chief Executive Officer and a director of Galil Medical. He was the President and Chief Executive Officer and a director of American Medical Systems Holdings, Inc., a medical device company, from 2005 to January 2008, where he also served as the President and Chief Operating Officer from 2004 to 2005, the Executive Vice President of Global Sales and Marketing and Chief Operating Officer from 2003 to 2004, and a Vice President and the General Manager of International from 2000 to 2002. Mr. Emerson has over 22 years of experience in the medical device industry. He was the General Manager and Finance Director in Singapore for Boston Scientific Corporation from 1998 to 2000. Mr. Emerson was the Vice President and Regional Financial Officer in Singapore for MasterCard International Incorporated from 1997 to 1998. He also held management positions with Baxter International Inc. from 1985 to 1997, most recently as the Vice President of Finance of its European Hospital Business division in Brussels, Belgium. Mr. Emerson is also a director of Wright Medical, a public company, and Incisive Surgical, a private company.

Jan Garfinkle specializes in medical technology investments, utilizing her educational background in biomedical engineering, extensive operating experience, and industry connections to select and nurture outstanding companies. Her investing activities primarily focus on FDA 510(k) and PMA medical device and diagnostics companies. Jan currently serves on the board of directors for HandyLab, VasoNova, Mirabilis Medica and NXThera Inc., and as an observer for Uptake Medical, BAROnova and Esperion Therapeutics.

Prior to founding Arboretum in 2002, Jan spent 20 years in senior management positions in entrepreneurial healthcare companies. Jan was Founder and President of Strategic Marketing Consultants, a consulting firm focused on the commercialization of healthcare technologies for start-ups and large medical device manufacturers. Earlier in her career, Jan worked for two successful medical device start-up companies, Advanced Cardiovascular Systems (ACS) and Devices for Vascular Intervention (DVI). Each of these companies was acquired by Eli Lilly and Company for more than $100 million and became the foundation for Guidant Corporation, which Eli Lilly later spun out in 1994. She joined each company early in its development and held key management roles in marketing, clinical research and sales. She began her career as a manufacturing engineer and production line manager for Proctor and Gamble.

Jan has served on a number of advisory boards focused on capital formation and enhancing the commercialization of promising technologies. She is a board member of the Michigan Venture Capital Association (MVCA) and is the past president of the MVCA. Additionally, she is a member of the Commercialization Advisory Board of the Global Cardiovascular Innovation Center (GCIC) at the Cleveland Clinic.

Jan earned a BS in Bioengineering from the University of California at Berkeley and an MBA from the Wharton School at the University of Pennsylvania.

Bruce German received his PhD from Cornell University, joined the faculty at the University of California, Davis in 1988, in 1997 was named the first John E. Kinsella Endowed Chair in Food, Nutrition and Health is currently professor, at University of California, Davis serves as senior scientific advisor at the Nestlé Research Center in Lausanne Switzerland and head of the Scientific Board of Lipomics Technologies Inc in California. His research interests include the structure and function of dietary lipids, the role of milk components in food and health and the application of metabolic assessment to personalizing diet and health.

Inderbir S. Gill, MD, MCh, is Chairman, Department of Urology, Cleveland Clinic, Cleveland, OH. He is professor of surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. After completing medical school, surgery residency, and urology residency in India, he moved to the USA in 1989, where he completed a 2-year fellowship in renal transplantation and renovascular surgery at the Cleveland Clinic, and a second urology residency at the University of Kentucky Medical Center in 1995.

After 2 years as associate professor at the University of Nebraska Medical Center, he joined Cleveland Clinic in 1997 as head, section of laparoscopic and robotic urology. From 2001-2003, he was executive director, the Minimally Invasive Surgery Center. In 2004, he was promoted as full professor of surgery. From 2006- 2007, he was vice chairman, department of urology. In 2008, Dr. Gill was named chairman, department of urology at the Cleveland Clinic.

Dr Gill has received many honors and awards. His minimally invasive team has won over 35 best paper/video awards at various annual meetings of the AUA and other urologic societies over the past 5-7 years. In 2005, the President of India awarded him the Dr. B. C. Roy National Award for Eminent Medical Person, the first time a physician living outside India has been selected for this singular national honor, which is not awarded annually. He was awarded the St. Paul’s Medal by the British Urological Association (BAUS) for 2006. This is the highest honor that can be bestowed by the BAUS. In 2006, Dr Gill was President of the 24th World Congress of Endourology and SWL, and, with his team, organized in Cleveland one of the most successful world congresses to date, with more than 1700 attendees from 62 countries. In 2008, he was elected President, Urologic Society for Transplantation and Renal Surgery. He has been listed in “Best Doctors in America” for several years now.

Dr Gill has authored or co-authored over 350 peer-reviewed original scientific papers, over 50 book chapters, and 8 Text-books. He is on the editorial board of 9 urologic journals, has been invited as visiting professor to more than 250 institutions & societies, and has performed live surgery demonstrations at over 55 centers worldwide. He was elected to the American Association of Genito-Urinary Surgeons in 2003 and became a member of the Society of Urologic Oncology in 2008. Dr. Gill’s primary focus is minimally invasive urologic oncology. He has amassed one of the world’s largest laparoscopic/robotic surgery experiences in approximately 4000 cases in the United States. A leader in minimally invasive nephron-sparing surgery for renal cancer, he has refined the techniques of partial nephrectomy and renal cryoablation, which his team has now performed in over 1500 patients. His team has made many novel contributions in flexible robotics, laparoscopic radical cystectomy and laparoscopic/robotic radical prostatectomy. Most recently, he and his team are working to further develop natural orifice translumenal endoscopic surgery (NOTES) and laparo-endoscopic single-site (LESS) surgery in urology, innovative novel concepts towards scar-free surgery. Dr. Gill’s team is widely recognized as being amongst the leading minimally invasive units in urology.

Michael is a General Partner at Flybridge Capital Partners focused on information technology, healthcare and medical technology investments. Among a range of general investment themes, Michael is currently focused on opportunities involving the convergence of healthcare and IT, technology-enabled business services, and technologies that address the physical security and homeland defense markets.

Michael currently represents the firm on the boards of BlueTarp Financial, MicroCHIPS, PolyRemedy, Predictive Biosciences, Protein Forest, T2 Biosystems and VidSys and led the firm’s investment in Magen BioSciences.

Michael founded IDG Ventures Atlantic in 2001 before it transitioned to Flybridge Capital Partners in 2008. Michael served on the board of International Data Group, the flagship Limited Partner for the IDG Ventures global network of funds.

Michael currently serves as Chairman of the New England Venture Capital Association where he served as President from 2005 to 2008. He is also on the investment committee of the Partners Innovation Healthcare Fund, a member of the Executive Business Advisory Council for Mass General Hospital for Children, and a trustee and on the investment committee of the Massachusetts Eye and Ear Infirmary. Additionally, Michael authors a column called “Nothing Ventured” for BioIT World magazine and blogs on the venture industry for Xconomy.

In previous positions, Michael was with Polaris Venture Partners, where he focused on both early-stage and later-stage financings for emerging growth companies. Before Polaris, Michael served as Senior Vice President and Founding Partner of GCC Investments, a $200 million private equity fund. Prior to GCC Investments, Michael was a Vice President and one of the early professionals at Wasserstein Perella & Co., an international merchant bank with a $1.0 billion private equity fund. Additionally, Michael was a member of the Mergers and Acquisitions Department of Morgan Stanley & Co. and worked in the Leveraged Buyout Group of Credit Suisse First Boston.

André Théodore Guay, MD, is currently clinical assistant professor of medicine at Harvard medical school and Director of the Center For Sexual Dysfunction at Lahey Clinic Northshore in Peabody. He is a senior staff physician in the Department of Endocrinology at the Lahey Clinic Medical Center, Burlington, MA.

After receiving his bachelor's degree from Boston College, Dr Guay received his MD degree from the New Jersey College of Medicine in 1968. His internship and residency in Internal Medicine were performed at Saint Vincent Hospital / U. Mass. Medical School in Worcester, MA. His specialty training in Endocrinology and Metabolism was carried out at the Mayo Clinic in Rochester, MN

After three years in the US Navy, where he was Head of Endocrinology, Chief of Clinical Research and held an appointment at Eastern Virginia Medical School, he joined the Lahey Clinic in Boston in 1977. He was Head of the Endocrinology Department for nearly 10 years, after which he started the Center For Sexual Function. He has published in the areas of reproductive endocrinology and neuroendocrinology. His current areas of interest are male and female sexual dysfunction, and specifically, male and female testosterone deficiency.

Joseph F. Hahn, MD, MBA, was appointed Chief of Staff of the Cleveland Clinic Health System and Vice-Chairman of the Board of Governors for The Cleveland Clinic in September, 2005. Dr. Hahn is responsible for the clinical divisions and the institutes, with over 1,900 professional staff members. In addition, Education, Research and Florida operations report to the Chief of Staff.

Previous to that appointment, Dr. Hahn was the Chairman of CCF Innovations since its establishment in 2000. As Chairman of CCF Innovations he was responsible for commercialization of all technology developed at the Cleveland Clinic.

Prior to CCF Innovations, Dr. Hahn was the longest serving Chairman of Surgery in the history of the Cleveland Clinic Foundation, having served as Division Chair from 1987 to October, 2003. As Surgery Chair, he managed an enormous growth in the CCF’s surgical capabilities, ultimately reaching a budget level of more than $600 million with more than 220 surgeons. Six of the surgical departments he was responsible for were rated in the top ten in the United States. Cardiothoracic surgery was ranked #1 for nine years in a row and continues in that position.

A noted neurosurgeon, Dr. Hahn has also served as Chairman of the Department of Neurosurgery and the head of the Pediatric Neurosurgery Section. He received his BA from Johns Hopkins University in 1964, his medical degree from the University of Virginia in 1968, his MBA degree from the Weatherhead School of Management in 1990, and was a flight surgeon in Southeast Asia. His wife Andrea is a distinguished artist. They have three grown children.

Eric Halvorson is the chief marketing officer for the Medical Systems Group of Olympus America Inc. He oversees the strategic positioning and product marketing for the company’s integrated medical, surgical and solutions product portfolio, as well as the newly acquired Gyrus ACMI businesses. Utilizing his extensive experience in all phases of therapeutic and diagnostic endoscopy marketing, Halvorson is responsible for enhancing Olympus’ position as a world leader in endoscopy, urology and repair services in the U.S. He also is committed to expanding the company’s rapidly growing surgical, ENT, endotherapy and healthcare solutions platforms.

A Minnesota native, Halvorson graduated from the University of Minnesota-Duluth, earning a bachelor of science in business administration in 1982. He quickly found his niche in the minimally invasive medical device arena, accumulating over 20 years of experience in the industry. In his career, he has held a variety of sales, marketing, international and general management positions for Boston Scientific, Baxter Healthcare and Smith and Nephew.

In 2003, Halvorson joined Olympus America to serve as vice president of marketing for its Medical Systems Group. Then in 2004, his expertise was leveraged to help grow the company’s emerging EndoTherapy business, most recently serving as that segment’s vice president and general manager. Under his strategic guidance, the EndoTherapy organization introduced a significantly expanded product line along with integrated devices, supporting a five-fold increase in sales.

Halvorson serves on the board of directors for the American Society for Gastrointestinal Endoscopy Foundation.

Halvorson resides in Center Valley, Pennsylvania, with his wife and daughter.

C. Martin Harris, MD, M.B.A., is the Chief Information Officer and Chairman of the Information Technology Division of Cleveland Clinic in Cleveland, Ohio. Additionally, Dr. Harris is Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the Internet.

Dr. Harris’ interest and expertise in the area of improving the practice of medicine through the innovative application of information technology, is reflected in his numerous appointments to national technology organizations including:

• Health & Human Services Board of Regents of the National Library of Medicine
• HIMSS Board Member
• Appointed to the President’s Commission on Care for America’s Returning Wounded Warriors
• Appointed to the Congressional Commission on Systemic Interoperability, which studies the steps required to develop a national health information network

Dr. Harris received his undergraduate and medical degrees from the University of Pennsylvania in Philadelphia. His residency training in general internal medicine was completed at The Hospital of the University of Pennsylvania. He completed a Robert Wood Johnson Clinical Scholar fellowship in General Internal Medicine at The University of Pennsylvania School of Medicine and holds a Masters in Business Administration in Healthcare Management from The Wharton School of the University of Pennsylvania.

At McKinsey, Nicolaus heads the Payor & Provider Healthcare Practice in Europe, the Middle East, and Africa and chairs McKinsey's work with national Health Systems globally. Over the past decade, Nicolaus has worked on more than 250 health care engagements in 17 health care systems on a broad set of issues, including health care system design, creating and managing payors, hospital strategy, and operations, as well as R&D and marketing of pharmaceuticals. He frequently speaks on and publishes health care topics. Prior to his time at McKinsey, Nicolaus worked in banking for 2 years. He holds a Master and Doctorate in Business Economics from the University of Muenster, Germany, as well as a Master in Public Administration from Harvard University, where he was a John J McCloy Scholar.

Chris Jennings is a more than two decade-long veteran of the Congress, the White House, and the private sector who currently is president of Jennings Policy Strategies (JPS), a consulting firm that serves clients that share a commitment to affordable, quality health care for all Americans. Clients include consumer groups, labor organizations, businesses, public and private health plan purchasers, generic drug manufacturers, and not-for-profit foundations. In this latter capacity, Mr. Jennings is currently the Co-Director (with former CMS Administrator Mark McClellan) of the Bipartisan Policy Center's health reform project with former Majority Leaders' Baker, Daschle, Dole and Mitchell. Earlier in 2008, he also served on the Democratic Platform Drafting Committee as well as a senior health care advisor to Senator Hillary Clinton's Presidential campaign.

From 1994 - 2001, Mr. Jennings served in the White House as senior health care advisor to President William Jefferson Clinton at the Domestic Policy and National Economic Councils. In this role, he was charged with developing and implementing the Administration's health care policy. Mr. Jennings made significant contributions to major, bipartisan health legislation, including the State Children's Health Insurance Program, the Health Insurance Portability and Accountability Act, the Mental Health Parity Act, the Food and Drug Administration Modernization Act, and many others. Mr. Jennings also coordinated and oversaw the health policy work of numerous Federal agencies, including the Office of Management and Budget and the Departments of Health and Human Services, Treasury, and Labor while leading efforts to communicate and advocate Administration health policy to the Congress, state and local governments, health care interest groups, and the media. Prior to joining the Clinton Administration, Jennings served as Committee staff for three U.S. Senators over almost a ten year period on Capitol Hill.

J. Stephen Jones is Chairman of the Department of Regional Urology at the Cleveland Clinic Glickman Urological and Kidney Institute, and is Associate Professor of Surgery (Urology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He earned a Bachelor of Science in Zoology at the J. William Fulbright College of Arts & Sciences at the University of Arkansas and MD at UAMS. After completing a six year urology residency at Vanderbilt University in 1992, he joined the Springfield Clinic in Missouri. Four years later, he assumed chairmanship of that program, one of the largest urology departments in North America at the time. Under his chairmanship, the Department of Urological Surgery became the highest rated non-residency urology program in America, according to U.S. News & World Report. With specialty interests in urological oncology and male sterilization, he holds appointment in the Section of Urological Oncology since 2000. He serves on both the CCF Division of Surgery Clinical Council and Regional Council.

In addition to clinical & administrative responsibilities, he is involved in basic science and clinical research involving bladder & prostate cancer and male sterilization. His work of almost 60 peer reviewed and non-peer reviewed publications has been published in the Journal of Urology, Urology, BJU International, European Urology, Journal of Endourology, Prostate Cancer and Prostatic Diseases, AUA Update, the American Journal of Urological Reviews, the Journal of Andrology, and Lasers in Surgery and Medicine, and he is the author of almost twenty book chapters. His book for the lay public, The Complete Prostate Book (Prometheus Books, Amherst NY. Foreword by Coach Rick Pitino), was published in August of 2005. His previous book, Overcoming Impotence (Prometheus Books, Amherst NY. Foreword by Senator Bob Dole), was published in 2003. He is Associate Editor of Operative Urology at the Cleveland Clinic (Humana Press) and Senior Editor of Prostate Biopsy: Techniques, Indications, and Complications (Humana). He serves as the Editor of Urology News, as Associate Editor of Urology, on the Editorial Board of BJU International, Advisory Board of Maximum Fitness Magazine, and is a former editorial board member for Urology Times. In addition, he is the Chairman of the Cryo Online Database (COLD) International registry.

Dr. Jones lives in the Cleveland suburb of Shaker Heights, OH, with his wife Kathryn and their two teenagers, Jared and Katie. Kathryn is a community activist involved in local issues, several community boards including the Shaker Schools Foundation Trustee, the League of Women Voters Ohio Board of Directors, and the LWV Cleveland and Ohio Education Funds. Their interests involve outdoor activities, including gardening, but their free time is most often occupied by the children’s academic and sporting events. Katie is a record-holding rower and former captain of the Shaker Heights Crew Team and now is a full-time student in the S.I. Newhouse College of Communications at Syracuse University. Jared plays football & track and debates vociferously for University School, winning the Ohio State Championship in 2007.

Dr. Anthony Kalloo is a Professor of Medicine at Johns Hopkins Hospital, Division of Gastroenterology. He is the Director of The Division of Gastroenterology and Hepatology with special interests in Natural Orifice Translumenal Endoscopic Surgery, therapeutic endoscopy, and sphincter of Oddi dysfunction. After receiving his medical degree at the University of West Indies Medical School, Dr. Kalloo interned at Port of Spain General Hospital in Trinidad and performed his Internal Medicine Residency Howard University Hospital in Washington, D.C., where he was also Chief Resident in Internal Medicine. He completed his fellowship training program at the combined Georgetown University, VA Medical Center and NIH program. He was an Instructor in Medicine at Georgetown University prior to joining the faculty at Johns Hopkins in 1988. He was an Associate Editor of Gastrointestinal Endoscopy. He is the founder and immediate past medical director of The Hopkins Gastroenterology and Hepatology Resource Center (www.hopkins-gi.org), a 3000 page multilingual web resource for patients and physicians. He has authored multiple scientific papers and book chapters. He has pioneered and has several patents including the use of Botulinum Toxin in the gastrointestinal tract, endoscopic cryotherapy and the winged biliary/pancreatic stent and others related to natural orifice surgery. He is the pioneer of Natural Orifice Translumenal Endoscopic Surgery, a technique that will enable abdominal surgery without the use of incisions. Dr. Kalloo is a past Panel Chair for Gastroenterology and Urology Devices with the United States Food and Drug Administration. He is a member of the Apollo group, a think-tank endoscopy group. Dr. Kalloo and the Division of Gastroenterology and Hepatology aim to advance the understanding, diagnosis, treatment and prevention of gastrointestinal and liver disease through patient care, education and research.

Jihad H. Kaouk, MD is an Associate Professor of Surgery and the Director of the Center for Advanced Robotics and Laparoscopic Innovations in the Glickman Urological & Kidney Institute at the Cleveland Clinic in Cleveland, Ohio.

Dr. Kaouk specializes in robotics and laparoscopic surgery and also has significant experience in ablative kidney therapies including cryoablation and radiofrequency ablation. He has authored 140 peer-reviewed publications and 12 book chapters.

Dr. Kaouk published on several innovations including single port laparoscopic surgery and various robotic urologic procedures.

Dr. Kaouk received a Cleveland Clinic innovator award in 2006 and several American Urological Association best abstracts and surgical video awards.

Larry Keeley is a partner at Monitor, and the president and co-founder of Doblin Inc. He is an acclaimed author, speaker, and teacher on the role of innovation and business. Over the last 25 years, Larry has advised hundreds of clients on how to use rational, repeatable methods to achieve innovation effectiveness. Larry was named by Business Week as one of the "Seven Gurus of Innovation." He is also on the faculty and Board of the IIT Institute of Design in Chicago and is a highly rated teacher at the Kellog Graduate School of Business.

Dr. John E. Kelly III is IBM senior vice president and director of Research. In this job he directs the worldwide operations of IBM Research, with more than 3,000 technical employees at eight laboratories in six countries around the world, and helps guide IBM’s overall technical strategy.

Dr. Kelly’s top priority as head of IBM Research is to stimulate innovation in key areas and quickly bring those innovations into the marketplace to sustain and grow IBM’s existing business, and to create the new businesses of IBM’s future. IBM applies these innovations to help our clients succeed.

Dr. Kelly also leads IBM’s worldwide intellectual property business as well as the company’s open source and open standards strategies and practices.

Prior to beginning his current assignment in July of 2007, Dr. Kelly was senior vice president of Technology and Intellectual Property, responsible for IBM’s technical and innovation strategies.

In 2000, Dr. Kelly was group executive for IBM’s Technology Group, where he was responsible for developing, manufacturing and marketing IBM’s microelectronics technologies, products and services.

Dr. Kelly joined IBM in 1980. Between 1980 and 1990, he held numerous management and technical positions related to the development and manufacturing of IBM’s advanced semiconductor technologies. In 1990, he was named director of IBM’s Semiconductor Research and Development Center. In 1994, he was appointed vice president of business process reengineering for the Microelectronics Division.

In 1995, he was named vice president of systems, technology and science for the IBM Research Division. In this role, Dr. Kelly was responsible for the company’s most advanced research activities. The following year, he was named vice president of strategy, technology and operations for the Microelectronics Division. In 1997, he was appointed vice president of server development (from work stations to supercomputers) for IBM. In January of 1999, he was appointed general manager of IBM’s Microelectronics Division, a position he held until August 2000.

Dr. Kelly received a Bachelor of Science degree in physics from Union College in 1976. He received a Master of Science degree in physics from the Rensselaer Polytechnic Institute in 1978 and his Doctorate in materials engineering from RPI in 1980. In 2004, he received an Honorary Doctorate of Science from The Graduate School at Union College.

Dr. Kelly is on the Board of Governors of The IBM Academy of Technology; a board member and former chairman of the Semiconductor Industry Association; a Fellow of the Institute of Electrical and Electronics Engineers, and on The Board of Trustees of Union College.

Dr Tom Kelly is the Director of the Lifesciences Division in Enterprise Ireland. He holds a BSc and PhD from the National University of Ireland - Galway and a Masters in Technology from the University of Sheffield, along with a Masters in Industrial Engineering from University College Dublin.

Enterprise Ireland is a government agency responsible for driving the development and internationalisation of Ireland’s indigenous industry. Lifesciences is critically important to Ireland’s economy and the Lifesciences Division provides a range of financial and non-financial support to accelerate the growth of companies ranging from small to medium size enterprises, to large global multinationals. The Division consists of 67 people specialising in international business development, technology management and organisational development.

Prior to his current appointment, Dr Kelly held a range of senior management positions in Enterprise Ireland including Director of High Potential Growth Companies, Technology Services and Director of the International Ceramics Research Centre.

Eric A. Klein, MD, is the Head of the Section of Urologic Oncology in the Urological Institute and a staff member in the Cancer Center at Cleveland Clinic. His clinical interests are all aspects of urologic oncology, including cancers of the prostate, bladder, testis and kidney, and including all major reconstructive procedures such as continent urinary diversion. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.

Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He is currently the National Medical Study Coordinator for the National Cancer Institute sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic Foundation.

Dr. Klein received his medical degree from University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.

Dr. Peter Klemm leads Predictive Biosciences overall to achieve key corporate milestones. He is the former Chief Executive Officer of GeneOhm Sciences, a molecular diagnostics company pioneering the rapid detection of bacterial organisms, including those known to cause healthcare-associated infections (HAIs). Dr. Klemm joined GeneOhm (founded in 2001) in May 2002 as CEO and oversaw the company’s acquisition by Becton Dickinson in February 2006 for $230 million. GeneOhm investors included Domain Associates, CHL Medical Partners, Kaiser Permanente Ventures, Partners HealthCare, Questmark Partners, Wasatch Advisors, and others.

Dr. Klemm was previously Chief Executive Officer of JOMED Inc., a Swiss-based company that develops and manufactures products for interventional cardiology, radiology and minimally invasive vascular surgery. Following JOMED's successful IPO in April 2000 and with the acquisition of Endosonics Inc, Dr. Klemm moved to the United States to integrate the companies and was appointed Chief Executive Officer of JOMED Inc. Prior to joining JOMED, he was SVP of R&D at Gruenenthal GmbH, a European pharmaceutical company, where Dr. Klemm established state of the art drug discovery technologies and central analgesic therapies. Prior to Gruenenthal, Dr. Klemm joined Aventis as Senior Scientist within the cardiovascular drug discovery unit and spent one year as a post doctoral fellow at the William Harvey Research Institute in London with Sir John Vane.

John Kurhanewicz, Ph.D. is a Professor in the Departments of Radiology, Urology and Pharmaceutical Chemistry at University of California, San Francisco, and is a member of the California Institute for Quantitative Biology and UCSF Cancer Center, and faculty in the UCSF-UCB Bioengineering Graduate Group. He is recognized internationally for his research in magnetic resonance imaging (MRI) and spectroscopic imaging (MRSI) of patients with prostate cancer, and is the Director of the UCSF Prostate Imaging Program. He has been awarded major grants for the development and application of MR metabolic imaging to prostate cancer patients, and has over 100 publications in this area. Other areas of research include; DNP hyperpolarized 13C spectroscopic imaging, diffusion and perfusion imaging of prostate cancer on high field MR scanners, and the identification of new biomarkers using a combination of ex vivo HR-MAS spectroscopy, pathology, genomics, and proteomics of tissue samples and bio-fluids. He is also very interested in the application of mutiparametric MR imaging techniques for MR guided prostate biopsies and therapy. He serves on several review panels for the National Cancer Institutes, National Institute of Health and American Cancer Society. He also has been a major contributor to meetings of the Radiologic Society of North America and International Society of Magnetic Resonance in Medicine with his courses in molecular and advanced imaging in oncology.

Woojin Lee, Ph.D.; President, Founder and Director, Cambridge Endoscopic Devices, Inc. Dr. Lee received his Ph.D. in robotics and mechanical engineering from M.I.T. A co-founder of endoVia Medical, Inc., he led the development of advanced surgical robotic systems for laparoscopic and endoluminal surgery. Dr. Lee is the primary inventor in 14 issued and 54 pending U.S. patents. Dr. Lee has close working relationships with an extensive network of surgeons and an intimate understanding of the minimally invasive surgery market. In addition to his Ph.D., he received his B.S. and his M.S. degrees in mechanical engineering from M.I.T.

Stephen Levin manages the editorial coverage of the medical device industry for FDC/Windhover following Elsevier's acquisition of Windhover Information. This includes the following publications: IN VIVO Magazine, START-UP Magazine, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet. Steve joined Windhover Information in 1997, specializing in covering medical devices, distribution, and legal issues, and also served as the company's General Counsel.

Prior to joining Windhover, Steve was Senior Counsel to the US Senate Permanent Subcommittee on Investigations where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, Steve was with the Federal Election Commission and the Department of Justice. Steve formerly was an Editor of Health Industry Today, a leading publication in the health care distribution industry.

Ross A. Longhini has served as Executive Vice President and Chief Operating Officer since August of 2006.  He also assumed the role of interim CEO from January – April 2008.  Previously Mr. Longhini served as Chief Technology Officer at AMS. Mr. Longhini has more than 20 years of experience in the field of medical device product development. From 1998 to 2002, he served in various management positions in Sulzer Spine-Tech of Minnesota including Vice President, Research and Development, Clinical & Regulatory. From 1991 to 1998, he was with I.V. Infusion Therapy of 3M which was sold to Gaseby in 1996, then purchased by Smiths Medical Systems in 1997. From 1983 to 1991, he was with 3M Dental Products.

Karen Licitra is a company group chairman for Johnson & Johnson and Worldwide Franchise Chairman for Ethicon Endo-Surgery, Inc., including the Advanced Sterilization Products business and Johnson & Johnson Medical, Canada. She was named company group chairman in July 2002.

Ms. Licitra began her Johnson & Johnson career in 1984 as a sales representative with Ethicon, Inc. She advanced through positions in sales and marketing, joining Ethicon Endo-Surgery, Inc., in 1991 as director of marketing. In 1996 she was promoted to vice president, product management. With the acquisition of the Biopsys Medical business in 1997, Ms. Licitra was named vice president, breast care management and she led the successful integration of that business. She became vice president and general manager, Ethicon Endo-Surgery, Inc., in September 2000, and she was promoted to president in December 2000, the position she held until being named to her present assignment.

Ms. Licitra serves as a member of the Board of Trustees of Rider University and St. Peter's Healthcare System Inc. Board of Trustees. She is also a member of the Board of the Campaign to End Obesity, committed to advancing national policy and platforms to combat obesity.

Born in Bridgewater, NJ, Ms. Licitra received a B.S. degree in marketing from Rider College.

Bruce W. Lytle, M.D is a cardiothoracic surgeon who has earned international recognition for his innovations in cardiac reoperations, aortic surgery, coronary artery bypass grafting and valve surgery. He has been instrumental in developing and refining surgical techniques in all these areas.

Dr. Lytle is the Chairman of the Heart and Vascular Institute at The Cleveland Clinic. He oversees the study and treatment of all aspects of cardiovascular disease carried out by the physicians in the Departments of Cardiovascular Medicine, Thoracic and Cardiovascular Surgery, and Vascular Surgery. He is also an active surgeon and is board-certified by the American Board of Surgery and the American Board of Thoracic Surgery

Lisa Martinez is the Founder and volunteers as the Executive Director for The Women’s Sexual Health Foundation (TWSHF). As a registered nurse and an attorney, she leads the foundation in providing accurate and up to date resources on sexual health information for women and health care professionals. Part of TWSHF’s mission is to educate the public and health care providers on how medical conditions including diabetes, cancer, medications, pelvic surgery, and physical disabilities may impact a woman’s sexual well being.

Her work with The Women’s Sexual Health Foundation draws on her strengths in both medicine and law as she advocates for education in female sexual health and funding for sexual health research. Whether addressing groups of international health care professionals as she did at the 17th World Congress of the World Association for Sexual Health in Montreal or women at the 2007 Women's Health Matters Forum & Expo in Toronto, an event attended by 21,000 women, Ms. Martinez speaks from the dual perspective as a breast cancer survivor and health care professional.

Ms. Martinez has written several educational brochures, consulted with health care institutions, and has been published in various professional journals, including The Female Patient and Nursing For Women’s Health. She has appeared on CBS News LA and ABC, and has been interviewed on various NPR programs. TWSHF has served as a source for multiple media concerns including CBS, The Wall Street Journal, and US News and World Report.

In the fall of 2003, Ms. Martinez was honored for her contribution in advancing women’s health issues by “Speaking for Women’s Health,” a non-profit organization that coordinates women’s health conferences across the United States.

She currently serves as a scientific and clinical advisor to The Alexander Foundation, and as a reviewer for the Association of Women's Health, Obstetric and Neonatal Nurses journal Nursing For Women’s Health.

Lisa Martinez may be contacted at LMartinez@twshf.org, and for more information about TWSHF, go to www.TWSHF.org.

Dana Mead joined Kleiner Perkins Caufield & Byers as a partner in May 2005 to work in the life sciences practice.

For the past 25 years, Dana's career has focused on identifying new medical technologies, developing new markets and therapies, and building world-class management teams. He has worked with physician thought leaders around the world representing 10 different medical specialties. At KPCB, Dana leverages experience gained from his venture-funded, start-up management roles and board participation to support entrepreneurs and innovators dedicated to making a real difference in the lives of millions suffering from life-limiting disease.

Prior to joining KPCB, Dana was President of Guidant Vascular Intervention, a fully integrated billion dollar division with over 4500 employees. Since joining Guidant in 1992, he held positions of increasing responsibility including Vice President and General Manager, Cardiac & Vascular Surgery; Vice President and General Manager, Stents, Vascular Intervention Group; President, Japan and A/P Operations based in Tokyo; and Vice President, Corporate Relations and Policy with responsibility for investor relations, corporate communications, corporate marketing and public policy initiatives. Prior to joining Guidant, Dana worked in various sales and marketing roles at Allergan, Inc. and Johnson & Johnson. A native of Connecticut, Dana received his Bachelor's degree from Lafayette College and holds an MBA degree from the University of Southern California. Dana serves on the boards of AesThera, Inc., Corventis, Navigenics, Inc., OtisMed Corporation, Sinexus, Inc., Synvascular, Invuity, Inc., Spinal Modulation, Inspire Medical Systems, Voyage Medical, the California Healthcare Institute (CHI), the Cardiovascular Research Foundation (CRF), and Lucile Packard Children's Hospital.

A senior leadership position in the Health Care area, capitalizing on her skills of leadership, strategic thinking, communication, technical expertise and high performance team building.

Frederic H. Moll, MD, is a Co-Founder of Hansen Medical and has served as the company's Chief Executive Officer and a Director since the company's inception in September 2002. In November 1995, Dr. Moll Co-founded Intuitive Surgical Inc., a medical device company, and served as its first Chief Executive Officer and later, its Vice President and Medical Director until September 2003. In 1989, Dr. Moll Co-founded Origin Medsystems, Inc., a medical device company, which later became an operating company within Guidant Corporation, a medical device company, following its acquisition by Eli Lilly in 1992. Dr. Moll served as Medical Director of Guidant's Surgical Device Division until November 1995. Dr. Moll holds a B.A. from the University of California, Berkeley, a M.S. from Stanford University and a MD from the University of Washington School of Medicine.

Dr. Moore received her medical degree from Albany Medical College in Albany, New York. After completing her internship and residency at Albany Medical College, she completed a two year fellowship in Female Pelvic Medicine & Reconstructive Surgery at Cleveland Clinic, Cleveland, OH. During her fellowship Dr. Moore was awarded the American Foundation for Urologic Disease Research Scholarship 2005-2007. She is currently a joint staff member staff at Cleveland Clinic Glickman Urological and Kidney Institute and the Institute of Obstetrics and Gynecology. She is an Assistant Professor in the Department of Surgery at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Her clinical interests include pelvic organ prolapse, incontinence, voiding dysfunction, female reconstructive surgery and female sexual dysfunction.

Dr. Moore has published extensively in her field and is an active member in the American Urologic Society, Society for Female Urology & Urodynamics, Society for Women in Urology and the American Urogynecologic Society.

As corporate vice president for the Health Solutions Group at Microsoft Corp., Peter Neupert is responsible for developing and driving the company's product and services strategy for health around the globe. Working with Chief Research and Strategy Officer Craig Mundie, Neupert identifies market opportunities and investments where Microsoft can provide disruptive technology innovations that empower users and enable transformation.

In his position leading the Health Solutions Group, Neupert uses software to address business and clinical productivity issues across enterprise and research organizations with the Microsoft Amalga family of products, as well as the personal health needs of the individual consumer through Microsoft HealthVault. Before rejoining Microsoft, Neupert served as president and chief executive officer of Drugstore.com Inc. from July 1998 to April 2001, and continued as chairman of the board of directors through September 2004. Neupert led Drugstore.com to become a top online retail store and information site for health, wellness, beauty and pharmacy products. In 2000, he received an Ernst & Young Entrepreneur of the Year award for his work at Drugstore.com.

Neupert served in various capacities at Microsoft from 1987 to 1998. He started at Microsoft as the director of operating systems responsible for shipping OS/2, and later was responsible for MSNBC as vice president of News and Publishing for the interactive media group.

Neupert served on President Bush's Information Technology Advisory Committee (PITAC) from 2003 to 2005. On that committee, he co-chaired the Health Information Technology subcommittee and helped drive the report "Revolutionizing Health Care Through Information Technology," published in June 2004 by PITAC. He is an active member of the Institute of Medicine's Roundtable on Evidence-Based Medicine and sits on the Pacific Health Summit Advisory Board, as well as the board of GlobalScholar.com. Neupert holds a master's degree in business administration from the Tuck School of Business at Dartmouth College and a bachelor's degree from Colorado College.

Stephen N. Oesterle, MD, joined the company in 2002 as Senior Vice President for Medicine and Technology. In this role, Steve provides executive leadership for Medtronic scientific research, formation of technological strategies and continued development of strong cooperative relationships with the world's medical communities, technical universities, financial institutions and emerging medical device companies.

Previously, Steve served as Associate Professor of Medicine at the Harvard University Medical School and as Director of Invasive Cardiology Services at Massachusetts General Hospital, Boston. A teacher and innovator in the field of cardiac catheterization, he has also developed and directed interventional cardiology programs at Good Samaritan Hospital, Los Angeles; at Georgetown University; and at Stanford University.

Steve is a 1973 summa cum laude graduate of Harvard College and received his medical doctorate from Yale University in 1977. He completed his internship and residency at Massachusetts General Hospital and also served a fellowship in interventional cardiology at Stanford.

Dr. Marie Fidela Paraiso is Chief of the Center of Urogynecology and Reconstructive Pelvic Surgery and Co- Director of therogram for Female Pelvic Medicine and Reconstructive Surgery. She has a dual appt. In the Obstetrics, Gynecology, and Women's Health Institute and the Glickman Urological and Kidney Institute. She is a Co- Investigator for the Pelvic Floor Disorders Network (a large NICHD grant funded group of 7 US centers) and on the Board of Directors for the American Urogynecologic Society and Advisory Board of the American Association of Gynecologic Laparoscopists. She has published over 80 peer review articles and book chapters and is a reviewer of 8 peer review journals. She serves as Quality Reassurance Officer of our department. She is best known for advanced laparoscopic procedures and robotics for pelvic organ prolapse and graft use in pelvic floor surgery. She has given over 100 invited lectures worldwide most recently for the Cleveland Clinic Downunder Conference for the Australian Gynecologic Endoscopy Society.

Gregory Piskun, MD, was CEO of Pnavel Systems from its inception through acquisition by Covidien in 2008. He is a pioneer of Single Incision Laparoscopic Surgery. He performed pioneering clinical work on trans-umbilical single incision laparoscopic surgery in 1997-1998, then patented and developed a unique single port laparoscopic system, including multi-cannula ports, curved laparoscopic instrumentation, and the associated method of operating via a small single body incision. Dr. Piskun is a Founder of Pnavel Systems, Inc. which was originated in 2003 for the purpose of developing proprietary methods and technologies in Single Port Laparoscopy.

Dr. Piskun graduated from Kalinin Medical Institute, Russia. He completed a Fellowship in Advanced Laparoscopic Surgery from The University of Pittsburgh Medical Center and Research Fellowship in Cancer Immunology at The Memorial Sloan-Kettering Cancer Center.

Kerry Pope, President and CEO co-founded Novare Surgical Systems in 1999 with Dr. Thomas J. Fogarty. Before co-founding Novare, Mr. Pope served as EVP, Sales and Marketing for Computer Motion after leaving Baxter International's Vascular Systems Division (VSD) where he served as Vice President and General Manager. Prior to his tenure with Baxter Intramed/VSD, Mr. Pope held management positions of increasing responsibility at Intramed Laboratories, Vitaphore Corporation, Vitalmetrics, Diasonics and American Hospital Supply Corporation. Mr. Pope also serves on the Board of Directors of TivaMed.

He entered the medical device industry after serving in the United States Air Force. Mr. Pope holds a B.S. in Business Administration from the University of Maryland.

Kevin M. Quilty, Senior Vice President of Sales and Marketing has over 25 years of sales, marketing and general management responsibility within healthcare services and technology companies. Mr. Quilty joined Endocare in 2001 and has worked previously within both the private and public sectors of this industry. Under his leadership, Endocare has built a direct sales and marketing team of 50 individuals. Armed with his well-trained team, they have successfully launched the modern generation of cryoablation technology for the treatment of prostate cancer and ablation of tumors in the kidney, lung, liver and palliative intervention (treatment of pain associated with metastases). Mr. Quilty previously served as the CEO of Qualidex (pathology services), and held management positions at Pointshare Inc. (Siemens., Health Information) and Paidos Health Management Services (Neonatal Case Management). During his tenure with Matria Healthcare, (formerly Tokos Medical Corporation, 1985 to 1997), Mr. Quilty escalated to the position of General Manager. From 1977 to 1985, he held a variety of positions at Baxter Healthcare Corporation. Mr. Quilty received his Bachelor of Science Degree in Political Science from State University of New York, Oneonta.

Dr. Raymond R. Rackley is Professor of Surgery at the Cleveland Clinic Lerner College of Medicine and is on staff within the Section of Voiding Dysfunction & Female Urology at the Glickman Urological Institute of the Cleveland Clinic. He is a seasoned medical device and pharmacotherapy professional with over 25 years of product development and management experience since earning his biomedical engineering degree from Duke University. After receiving his medical degree from Case Western Reserve University, Dr. Rackley completed his urology residency, as well as, fellowship training in Pelvic Medicine and Reconstructive Surgery at the Cleveland Clinic. His clinical specialty interests in pelvic health conditions are in the areas of innovation regarding pharmacotherapy, neuromodulation, and minimally invasive methods and devices for diagnostics and interventions. His basic science expertise are in the areas of translational signal transduction work in Interstitial Cystitis, regenerative/ stem cell applications in Urinary Incontinence and Bladder Dysfunctions, neuromodulation therapies of pelvic health conditions, and more recently, commercial applications for sub-micron / nano-nozzle technologies.

Dr. Rackley has held consulting management, Board, and advisory board positions within large public, non-profit, early stage startup medical services, medical device and pharmaceutical companies that address the diverse needs within Pelvic Health. His leadership experience is broad in regards to designing, manufacturing, regulatory approvals and compliance processes, clinical trials, payor reimbursement, distribution, marketing & sales, and world-wide adoption of innovations in pharmacotherapy, minimally invasive surgical instrumentation, implantable devices, neuromodulation, and non-invasive diagnostic and therapeutics.

Dr. Rackley has served as the principal or co-PI investigator on NIH, institutional, and industry grants; has authored over 150 publications in clinical and basic science topics in pelvic health; and continues to serve as a reviewer for the leading peer-reviewed journals in Pelvic Health, Data and Safety Boards for the NIH, and has recently been elected to the Executive Board of the Society of Female Urology and Urodynamics, the leading Society for Pelvic Health Reconstructive Surgeons.

Mr. Rein served for 15 years as the Founder and Managing General Partner of Canaan Partners. In addition to his role as the Managing General Partner at Canaan Partners, Mr. Rein was responsible for Canaan’s Life Sciences Investment Practice. Prior to Canaan Partners, for four years he was President and CEO of GE Venture Capital Corporation. Mr. Rein has extensive experience with small and mid-sized companies, including the supervision of all investments made by GE Venture Capital during his tenure as President. Mr. Rein joined the General Electric Company (“GE”) in 1979 and directed several of GE's lighting businesses as general manager before joining the venture capital subsidiary. He has also worked for Transaction Systems, Inc., a strategic consulting firm, as a Vice President; with Gulf Oil Corporation as Director of Corporate Planning; and with Polaroid Corporation in several manufacturing positions. Mr. Rein has served on the boards of directors of over 20 public and private entrepreneurial companies, including: Cell Pathways, OraPharma (acquired by Johnson & Johnson), National MD (acquired by GE), OmniSonics, GenVec (NASDAQ: GNVC), CardioNet (NASDAQ: BEAT) and Spine Wave, and was an investor in Praecis Pharmaceuticals (NASDAQ: PRCS). Currently, Mr. Rein serves on the Board of Directors of Anadigics (NASDAQ: ANAD), CardioNet (NASDAQ: BEAT) and Spine Wave. Previously, Mr. Rein was a member of the Board of Directors of the National Venture Capital Association (“NVCA”) and was a recipient of the 2002 NVCA Outstanding Service Award. Mr. Rein also serves as a Trustee of the Cleveland Clinic, and is a member of the Clinic’s Research and Education, Finance and Budgeting, and International and Emerging Opportunities committees. Mr. Rein is Chairman of the Industrial Advisory Board of Cleveland Clinic Innovations andis also a member of its Investment Committee. He also serves as a Trustee of the University of Virginia Darden School of Business Foundation, where he is a member of the Executive Committee and Chairman of the Investment Committee.

Mr. Rein attended Emory University and Oglethorpe College (1968) and holds an M.B.A. from the Darden School at the University of Virginia (1973).

John C. Rewcastle, Ph.D., is the Medical Director of EDAP-TMS. He is responsible for the global clinical research programs of the company including the IDE program in the United States aimed at securing FDA approval and the European post market approval clinical program. He facilitates the creation of a published body of evidence for the clinical story behind HIFU which serves as the foundation of EDAP's regulatory, marketing and reimbursement programs.

Dr. Rewcastle has a PhD in medical physics and is also an Adjunct Professor of Radiology at the University of Calgary, Canada. He specializes in the development of minimally invasive technologies from both a basic science and clinical application prospective. In the past ten years he has published over 35 papers in peer reviewed medical journals, written several text book chapters and has made over 100 presentations at conferences around the world. He has also authored a series of papers comparing emerging technologies for the treatment of prostate cancer with traditional therapies.

Prior to EDAP he worked with Endocare in the establishment of cryoablation as a treatment option for localized prostate cancer. In this role he designed and established a patient registry, participated in a randomized clinical trial comparing cryoablation to radiation therapy and worked with many physicians to organize and publish their outcomes. Previously, he served as Chief Scientific Officer of Sanarus Medical, a medical technology company focused on women's health.

Dr. Riner is president of his own advisory and consulting firm, which he started in l980. He has served as a consultant and professional advisor to medical practices, health systems, professional medical associations, the insurance industry, pharmaceutical companies, universities and medical device companies on issues having bearing on the interface of the business community with those providing health care services or the supplying or development of healthcare products. He has also served as a member of the executive management team for one of the largest health care systems in the United States. He has participated in the formation of numerous strategic alliances, mergers and acquisitions within the healthcare field. He serves as a member of numerous professional societies and he is editor for a section of a publication focused on healthcare economics and healthcare business strategies, which has domestic and international readership (35 countries).

Mr. Ring was named Chairman and Chief Executive Officer for C. R. Bard, Inc. as of August 8, 2003. He joined Bard in June 1992 as Corporate Vice President – Human Resources and was promoted to Group Vice President – International in December 1993. In November 1995, he was given additional responsibility for Interventional Cardiology and Electrophysiology. In January 1997, he also assumed additional responsibility for the Cardiac Assist and Cardiopulmonary Divisions and in April 1997, he was promoted to Group President for Coronary Vascular Products. In 1999, he was named Group President for Bard Electrophysiology and Peripheral Vascular Products and in 2002 was given additional responsibility for Bard Access Systems, Bard Europe and Corporate Healthcare Services.

Prior to Bard, he worked for Abbott Laboratories for nearly 10 years, most recently as Director of Personnel for the Hospital Products Division. Before that, he was General Manager for Abbott’s Australian, New Zealand and Indonesian operations, residing in Sydney. Prior to that, he was Director of Personnel for Pacific/Asia/Africa and Europe. From 1984 to 1986, he was also Director of Personnel for Latin America & South East Asia. He started at Abbott in 1983 as Assistant Personnel Manager for the Pharmaceutical Division. Before joining Abbott, Mr. Ring was employed by The General Motors Corporation. Mr. Ring has a B.S. in Industrial and Labor Relations from Cornell University.

He is a trustee for the Foundation of The University of Medicine & Dentistry of New Jersey and the HealthCare Institute of New Jersey, and serves on the Cornell University Life Sciences Advisory Board. Mr. Ring is also a member of the Healthcare Research Development Institute and a member of the Board of Directors for C. R. Bard, Inc., AdvaMed, the medical device industry association, The CIT Group and NAM (National Association of Manufacturers).

David B. Robinson, MD, is a Board certified Obstetrician/Gynecolologist who practiced Obstetrics and Gynecology for 30 years as a member of Lincoln Center Obstetrics and Gynecology, P.A., a single specialty OB/GYN private practice in Topeka, Kansas. For the last 12 years of his practice he specialized in the treatment of female urinary incontinence and pelvic reconstructive surgery. During this period, he also served as an Associate Professor of Obstetrics and Gynecology for the University of Kansas School of Medicine. In November, 2005, he accepted the position of Medical Director, WorldWide, for ETHICON Women's Health and Urology, a Johnson and Johnson Company.

He is the author of multiple manuscripts, videos and presentations on pelvic floor dysfunction. He remains an active member of several professional organizations, including , the American College of Obstetrics and Gynecology (ACOG), the American Association of Gynecologic Laparoscopy (AAGL), the American Urogynecologic Society (AUGS), the International Continence Society (ICS), the International Urogynecology Association (IUGA), and the American Urology Association (AUA).

Richard Roth serves as CNN's senior U.N. correspondent. Based in New York, Roth has covered the U.N.'s role and responses to the war in Iraq and a variety of reports about American politics including the 2008 US presidential elections and the current financial crisis. He has also reported on the Russia-Georgia conflict from the diplomatic perspective at the UN, the recent death of Heath Ledger and the resignation of New York Gov. Eliot Spitzer.

As part of this role, Roth was also host of Diplomatic License, CNN's former global program devoted to coverage of the United Nations.

For the past decade, Roth has reported from the U.N. headquarters in New York City on several international crises, including Iraq, North Korea and Bosnia. In 2002 and 2003, he reported extensively on the escalating tensions between the United States and Iraq, the weapons inspection process then the ensuing war with Iraq. He also has covered various U.N. global conferences concerning issues such as social development in Copenhagen, women in China and the population in Cairo.

Robert E. Rubin is a Director and Senior Counselor to Citigroup Inc. and has been involved with financial markets and our nation's public policy debate all of his professional life.

Mr. Rubin began his career in finance at Goldman, Sachs & Company in New York City in 1966. Mr. Rubin served as Vice-Chairman and Co-Chief Operating Officer from 1987-1990 and as Co-Senior Partner and Co-Chairman from 1990-1992. Before joining Goldman, he was an attorney at the firm of Cleary, Gottlieb, Steen & Hamilton in New York City.

Alfred joined Google in November of 2007 and is responsible for the research across Google and also a growing collection of special engineering initiatives - projects like Google Health.

Previously, Alfred was Vice President of Strategy and Technology IBM's Software Business, Vice President of Services and Software Research across IBM, and a General Manager in the Software Business where he led products such as CICS and WebSphere. He was also founder and CEO of Transarc Corporation, a pioneer in distributed transaction processing and wide area file systems that was acquired by IBM in 1994. Previously Alfred was Associate Professor of Computer Science at Carnegie Mellon University, specializing in highly reliable, highly scalable distributed computing.

Alfred received his Ph.D. in Computer Science from Stanford and his A.B. in Applied Mathematics from Harvard. He has published numerous articles and is a member of the National Academy of Engineering, a Fellow of the IEEE and ACM, and the recipient of the 2001 IEEE Computer Society's Tsutomu Kanai Award for work in scalable architectures and distributed systems.

David R. Strand,  Cleveland Clinic

Michael Tarnoff, MD,  Surgical Devices Global Business Unit

Holly L. Thacker, MD,  Cleveland Clinic

Tommy G. Thompson,  Former Secretary, Department of Health and Human Services

James R. Tobin,  Boston Scientific

Wulf H. Utian, MD, PhD, DSc.(Med),  The North American Menopause Society

Sandip P. Vasavada, MD,  Cleveland Clinic

Clement Vidal,  EndoControl

Kobi Vortman, PhD,   InSightec Ltd.

Michael C. Wiemann, M.D.,  St. John Health

Sen. Ron Wyden,  (D-Ore.)

Craig B. Wynett,   The Procter & Gamble Company